» Articles » PMID: 39164508

Liver Stiffness As a Prognostic Parameter and Tool for Risk Stratification in Advanced Cardiac Transthyretin Amyloidosis

Abstract

Background: In light of increasing therapeutic options, risk stratification of advanced cardiac transthyretin amyloidosis (ATTR-CA) is gaining clinical importance to avoid ineffective treatments. Liver stiffness as a marker of hypervolemia and hepatic congestion might predict mortality in advanced ATTR-CA and allow to identify patients at highest risk.

Methods: Proven ATTR-CA patients underwent repeated vibration-controlled transient elastography (VTCE) and standardized serial workup within the local amyloidosis cohort study AmyKoS. Spearman correlation analyses and Cox regressions were performed to evaluate the prognostic value.

Results: 41 patients with ATTR-CA were included with median age of 76.6 (55.1-89.1) years, of which 90.2% were male and > 92% wild-type ATTR-CA. In total, 85 VCTE examinations were performed. Median follow-up was 43.7 (2.4-75.6) months; 26.8% of the patients died. At the first clinical evaluation, median left ventricular (LV) absolute global longitudinal strain (GLS) was 11.4 (5.2-19.0) % and median liver stiffness was 6.3 (2.4-22.9) kPa, both significantly correlated with mortality. NT-proBNP possessed statistically significant predictive power in ATTR-CA with more preserved LV function (absolute GLS ≥ 10), whereas stiffness seemed to be more discriminative for ATTR-CA with absolute GLS < 10. The use of alternative congestion surrogates such as liver vein dilation and tricuspid regurgitation peak velocity (tr-v) showed congruent results.

Conclusion: Liver stiffness shows prognostic value regarding all-cause mortality and allows risk stratification in advanced ATTR-CA, particularly in those with markedly impaired longitudinal LV function. These results are transferable to other congestion surrogates.

References
1.
Ihne S, Morbach C, Obici L, Palladini G, Stork S . Amyloidosis in Heart Failure. Curr Heart Fail Rep. 2019; 16(6):285-303. DOI: 10.1007/s11897-019-00446-x. View

2.
Grogan M, Scott C, Kyle R, Zeldenrust S, Gertz M, Lin G . Natural History of Wild-Type Transthyretin Cardiac Amyloidosis and Risk Stratification Using a Novel Staging System. J Am Coll Cardiol. 2016; 68(10):1014-20. DOI: 10.1016/j.jacc.2016.06.033. View

3.
Gillmore J, Damy T, Fontana M, Hutchinson M, Lachmann H, Martinez-Naharro A . A new staging system for cardiac transthyretin amyloidosis. Eur Heart J. 2017; 39(30):2799-2806. DOI: 10.1093/eurheartj/ehx589. View

4.
Cappelli F, Martone R, Gabriele M, Taborchi G, Morini S, Vignini E . Biomarkers and Prediction of Prognosis in Transthyretin-Related Cardiac Amyloidosis: Direct Comparison of Two Staging Systems. Can J Cardiol. 2020; 36(3):424-431. DOI: 10.1016/j.cjca.2019.12.020. View

5.
Aus dem Siepen F, Bauer R, Voss A, Hein S, Aurich M, Riffel J . Predictors of survival stratification in patients with wild-type cardiac amyloidosis. Clin Res Cardiol. 2017; 107(2):158-169. DOI: 10.1007/s00392-017-1167-1. View